Alan Carr analyst

Currently out of the existing stock ratings of Alan Carr, 104 are a BUY (88.89%), 13 are a HOLD (11.11%).

Alan Carr

Work Performance Price Targets & Ratings Chart

Analyst Alan Carr, carries an average stock price target met ratio of 68.46% that have a potential upside of 38.31% achieved within 471 days. Previously, Alan Carr worked at NEEDHAM.

Alan Carr’s has documented 219 price targets and ratings displayed on 29 stocks. The coverage was on Healthcare, Industrials sectors.

Most recent stock forecast was given on RYTM, Rhythm Pharmaceuticals at 11-Dec-2025.

Wall Street Analyst Alan Carr

Analyst best performing recommendations are on GNCA (GENOCEA BIOSCIENCES).
The best stock recommendation documented was for GNCA (GENOCEA BIOSCIENCES) at 3/5/2014. The price target of $176 was fulfilled within 2 days with a profit of $45.04 (34.39%) receiving and performance score of 171.96.

Average potential price target upside

CRSP Crispr Therapeutics AG GILD Gilead Sciences MRNA Moderna PHAT Phathom Pharmaceuticals VRTX Vertex Pharmaceuticals ACAD ACADIA Pharmaceuticals ALNY Alnylam Pharmaceuticals BHVN Biohaven Pharmaceutical Holding Co Ltd CARA Cara Therapeutic ICPT Intercept Pharmaceuticals LXRX Lexicon Pharmaceuticals TRVN Trevena TTPH Tetraphase Pharmaceuticals VIR Vir Biotechnology NBIX Neurocrine Biosciences RYTM Rhythm Pharmaceuticals VVUS VIVUS ZEAL Zealand Pharma A/S ADR AKAO Achaogen ALBO Albireo Pharma ARNA Arena Pharmaceuticals CDTX Cidara Therapeutics GNCA Genocea Biosciences NBRV Nabriva Therapeutics AG RGLS Regulus Therapeutics TBPH Theravance Biopharma TCDA Tricida CAR Avis Budget Group PLRX Pliant Therapeutics 

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 17-Jan-2018

$110

$60.49 (122.18%)

$105

23 days ago
(17-Mar-2026)

27/33 (81.82%)

$59.91 (119.60%)

235

Buy Since 28-Oct-2019

$76

$26.49 (53.50%)

$74

1 months 23 days ago
(17-Feb-2026)

2/16 (12.5%)

$22.83 (42.94%)

24

Hold Since 05-Aug-2025

$45

$-4.51 (-9.11%)

$40

1 months 27 days ago
(13-Feb-2026)

2/7 (28.57%)

$-8.07 (-15.21%)

46

Buy Since 16-Feb-2022

$82

$32.49 (65.62%)

$80

1 months 27 days ago
(13-Feb-2026)

8/27 (29.63%)

$28.93 (54.51%)

214

Buy Since 13-Feb-2026

$74

$24.49 (49.46%)

1 months 27 days ago
(13-Feb-2026)

1/3 (33.33%)

$20.93 (39.44%)

29

Show more analysts

Please expand the browser size to see the chart

Which stock is Alan Carr is most bullish on?

Potential upside of $58.71 has been obtained for RYTM (RHYTHM PHARMACEUTICALS)

What Year was the first public recommendation made by Alan Carr?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?